Search results
Results From The WOW.Com Content Network
Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010. [13][14][15][16] In January 2015, secukinumab was approved in the United States and in the European Union to treat adults with moderate-to-severe plaque psoriasis. [17][18][6] It is the first IL17A inhibiting drug ever approved. [12] In January ...
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022. [4][5] Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to ...
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. [ 2 ] Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. [ 6 ][ 7 ] Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic ...
Luminespib ( INN, [ 2] previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis [ 3] and licensed to Novartis. [ 4]
A new study found a link between SGLT-2 inhibitors and a significantly lower risk of dementia in people with diabetes. Here's what doctors say about the link.
Derek Lowe (chemist) Derek Lowe is a medicinal chemist working on preclinical drug discovery in the pharmaceutical industry. Lowe has published a blog about this field, "In the Pipeline", since 2002 [1] and is a columnist for the Royal Society of Chemistry 's Chemistry World. [2]
Brolucizumab sold under trade name Beovu among others, is a humanized single-chain antibody fragment for the treatment of neovascular (wet) age-related macular degeneration (AMD). [6][5] The most common side effects are reduced visual acuity, cataract (clouding of the lens in the eye), conjunctival haemorrhage (bleeding at the front of the eye) and vitreous floaters (spots in the vision). [6 ...
Sacubitril/valsartan can be used instead of an ACE inhibitor or an angiotensin receptor blocker in people with heart failure and a reduced left ventricular ejection fraction (LVEF), [17][9] alongside other standard therapies (e.g. beta-blockers) for heart failure. [10][11][18] To investigate its use for heart failure in those with a preserved LVEF (HFpEF), Novartis funded the PARAGON-HF trial ...